Systemic Autoimmune Diseases and Recurrent Pregnancy Loss: Latest Advances in Diagnosis and Care
For 1–2% of couples trying to start a family, recurrent pregnancy loss (RPL)—losing two or more pregnancies before 24 weeks—casts a shadow over their journey. While causes like genetics, hormones, or anatomy are well-known, recent research highlights a critical but often overlooked factor: systemic autoimmune diseases. These conditions, where the immune system mistakenly attacks healthy tissue, can disrupt pregnancy in ways many people don’t realize.
Researchers from West China Second University Hospital, Sichuan University—Rui Gao, Xun Zeng, and Lang Qin—recently reviewed how three key autoimmune diseases link to RPL and what’s new in diagnosis and treatment. Their work, published in Chinese Medical Journal (2021), offers clarity for patients and providers alike.
Antiphospholipid Syndrome (APS): The Clotting Connection
APS is driven by antiphospholipid antibodies (aPL)—proteins that trigger blood clots or damage the placenta. When pregnancy loss is the main symptom, it’s called obstetric APS (OAPS). To diagnose OAPS, a woman must have:
- One clinical sign (e.g., losing a fetus at ≥10 weeks or multiple early miscarriages)
- One lab sign (positive aPL tests like lupus anticoagulant, anticardiolipin, or anti-beta-2 glycoprotein I antibodies).
But many women with RPL don’t fit these “classical” criteria. Enter non-criteria APS (NOAPS), a term for those with one classical and one non-classical feature (e.g., two unexplained IVF failures or low-level aPL). While NOAPS helps fill gaps, its rules are still evolving—researchers are working to make them more precise.
To guide care, doctors use risk stratification:
- High-risk: Persistent aPL (two+ tests 12 weeks apart), multiple aPL types (e.g., lupus anticoagulant + anticardiolipin), or very high antibody levels.
- Low-risk: Isolated, mild aPL that goes away.
High-risk women get more aggressive care—like low-dose aspirin (LDA) + low molecular weight heparin (LMWH)—to prevent clots or pregnancy loss. For those with NOAPS, treatment depends on their individual risk.
Undifferentiated Connective Tissue Disease (UCTD): The “Mild” Autoimmune Link
UCTD is a “catch-all” for mild autoimmune symptoms (e.g., joint pain, fatigue) paired with a positive antinuclear antibody (ANA) test (titers ≥1:80). It’s the most common autoimmune disease in pregnant women—affecting up to 2.5%—and carries a 9–21% risk of RPL.
Even women with positive ANA without a clear UCTD diagnosis are more likely to have RPL, studies show. To standardize care, researchers now use pregnancy loss-associated UCTD (PLUCTD) for women with unexplained RPL and positive ANA.
For PLUCTD, experts recommend:
- Starting hydroxychloroquine (HCQ) 3–6 months before trying to conceive (it’s safe and reduces risk).
- Low-dose prednisone (≤10 mg/day) during pregnancy if the disease might worsen.
- Monitoring blood clotting levels—some women need LDA or LMWH to prevent clots.
If pregnancy loss still happens despite this care, it’s called “refractory PLUCTD”—a area where more research is urgently needed.
Systemic Lupus Erythematosus (SLE): Balancing Disease and Pregnancy
SLE—an autoimmune disease that attacks organs like the kidneys or joints—most often affects women of childbearing age. Pregnancy is high-risk: SLE flare-ups, preeclampsia, and RPL are common. The biggest risk factor for RPL in SLE? Positive aPL (the same antibodies linked to APS).
For women with SLE and RPL, the first rule is stabilize the disease before pregnancy. Active SLE (e.g., kidney inflammation, high blood pressure) or teratogenic (birth-defect-causing) drugs must be addressed 6 months before trying to conceive. Safe alternatives like HCQ or cyclosporine A (CsA) replace risky meds.
During pregnancy, doctors monitor:
- Disease activity: Blood tests for kidney function, anti-dsDNA antibodies, and complement proteins (C3/C4).
- Pregnancy health: Ultrasounds, blood pressure, and fetal growth.
HCQ is recommended throughout pregnancy to prevent flare-ups and RPL. If SLE worsens, low-dose prednisone is added. For severe cases, safer immunosuppressants like azathioprine (AZA) or tacrolimus may be used—always in collaboration with a rheumatologist.
Gaps and Hope: What We Still Need to Learn
While progress has been made, big questions remain:
- What about aPL-positive women who don’t meet NOAPS criteria? Basic science suggests a link to RPL, but human studies are mixed. Doctors still monitor these women closely—especially their blood clotting—since they might develop NOAPS later.
- Better NOAPS criteria: The current rules are too vague; researchers are working to make them more precise.
- Refractory cases: For women who lose pregnancies despite treatment, there’s no standard care—yet. Exploratory therapies are being tested.
The Takeaway for Patients and Providers
If you’ve experienced RPL, asking your doctor about autoimmune screening (e.g., ANA, aPL tests) could be a critical step. For providers, the review emphasizes personalized care: using risk stratification for APS, standardizing PLUCTD care, and prioritizing SLE stabilization before pregnancy.
While RPL and autoimmune diseases can feel overwhelming, these advances offer hope. As the authors note: “Understanding how systemic autoimmune diseases cause RPL—and how to treat them—brings us closer to helping more couples build their families.”
Rui Gao, Xun Zeng, and Lang Qin. “Systemic autoimmune diseases and recurrent pregnancy loss: research progress in diagnosis and treatment.” Chinese Medical Journal (2021). doi.org/10.1097/CM9.0000000000001691
Was this helpful?
0 / 0